Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma

Abstract

Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T‐cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high‐dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T‐cell therapy, BsAbs, or long‐term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high‐risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.